Assessing VEGF mRNA and miR-494 expression in peripheral blood collected from patients suffering from oral squamous cell carcinoma
Abstract
Introduction: Oral squamous cell carcinoma accounts for 2% of all cancers and also is one of the top 10 causes of death in humans. The goal of this article is to assess changes of VEGF mRNA and miR-494 expression. Materials and Methods: We chose 30 patients with OSCC and 30 healthy people (as a controlled group) and assess the rate of VEGF mRNA and miR-494 expression in peripheral blood with real-time PCR technique.Findings: VEGF mRNA marker was positive in 24 out of 30 patients. Also, miR-494 was positive in 20 out of 30 patients. Results: Overall based on this article’s findings, results could count as a diagnostic screening test for OSCC detection in early steps of cancer.
1. Jou Y-J, Lin C-D, Lai C-H, Tang C-H, Huang S-H, Tsai M-H, et al. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages. Clinica Chimica Acta. 2011;412(15-16):1357-65.
2. Jou Y-J, Lin C-D, Lai C-H, Chen C-H, Kao J-Y, Chen S-Y, et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Analytica chimica acta. 2010;681(1-2):41-8.
3. Avissar M, Christensen BC, Kelsey KT, Marsit CJ. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clinical Cancer Research. 2009;15(8):2850-5.
4. Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. European journal of cancer. 2011;47(8):1127-37.
5. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. The international journal of biochemistry & cell biology. 2010;42(8):1273-81.
6. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Critical reviews in oncology/hematology. 2012;81(2):103-22.
7. Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA‐494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell proliferation. 2012;45(1):32-8.
8.Xin H, Zhong C, Nudleman E, Ferrara N. Evidence for pro-angiogenic functions of VEGF-Ax. Cell. 016;167(1):275-84. e6.
9.Kacher J. Oral and maxillofacial pathology. Case of the month. Histoplasmosis. Texas dental journal. 2013;130(3):198, 232.
10. Zukanović A, Gržić R. Dental management of the medically compromised patient. Elsevier Mosby; 2012.
11. Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2011;717(1-2):1-8.
12. Benlloch S, Galbis J, Peiro F, Alenda C, Rodriguez-Paniagua J, Sanchez-Paya J, et al. Role of CEA, PLUNC and CK19 mRNA expression in lymph nodes from resected stage I non-small cell lung cancer (NSCLC) patients (p) as markers of occult micrometastasis. A pilot study. Journal of Clinical Oncology. 2005;23(16_suppl):9654-.
13. Grunnet M, Sorensen J. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung cancer.2012;76(2):138-43.
14. Benedíková A, Srovnal J, Szkorupa M, Skalický P, Chudácek J, Bohanes T, et al. Biomarkers in the detection of minimal systemic dissemination in lung cancer patients. Rozhledy v chirurgii: mesicnik Ceskoslovenske chirurgicke spolecnosti. 2012;91(4):209-15.
15. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. Journal of clinical oncology. 2002;20(6):1692-703.
16. Wang W, Songlin P, Sun Y, Zhang B, Jinhui W. miR-21 inhibitor sensitizes human OSCC cells to cisplatin. Molecular biology reports. 2012;39(5):5481-5.
17. Nayak S, Goel MM, Chandra S, Bhatia V, Mehrotra D, Kumar S, et al. VEGF-A immunohistochemical and mRNA expression in tissues and its serum levels in potentially malignant oral lesions and oral squamous cell carcinomas. Oral oncology. 2012;48(3):233-9.
2. Jou Y-J, Lin C-D, Lai C-H, Chen C-H, Kao J-Y, Chen S-Y, et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Analytica chimica acta. 2010;681(1-2):41-8.
3. Avissar M, Christensen BC, Kelsey KT, Marsit CJ. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clinical Cancer Research. 2009;15(8):2850-5.
4. Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. European journal of cancer. 2011;47(8):1127-37.
5. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. The international journal of biochemistry & cell biology. 2010;42(8):1273-81.
6. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Critical reviews in oncology/hematology. 2012;81(2):103-22.
7. Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA‐494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell proliferation. 2012;45(1):32-8.
8.Xin H, Zhong C, Nudleman E, Ferrara N. Evidence for pro-angiogenic functions of VEGF-Ax. Cell. 016;167(1):275-84. e6.
9.Kacher J. Oral and maxillofacial pathology. Case of the month. Histoplasmosis. Texas dental journal. 2013;130(3):198, 232.
10. Zukanović A, Gržić R. Dental management of the medically compromised patient. Elsevier Mosby; 2012.
11. Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2011;717(1-2):1-8.
12. Benlloch S, Galbis J, Peiro F, Alenda C, Rodriguez-Paniagua J, Sanchez-Paya J, et al. Role of CEA, PLUNC and CK19 mRNA expression in lymph nodes from resected stage I non-small cell lung cancer (NSCLC) patients (p) as markers of occult micrometastasis. A pilot study. Journal of Clinical Oncology. 2005;23(16_suppl):9654-.
13. Grunnet M, Sorensen J. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung cancer.2012;76(2):138-43.
14. Benedíková A, Srovnal J, Szkorupa M, Skalický P, Chudácek J, Bohanes T, et al. Biomarkers in the detection of minimal systemic dissemination in lung cancer patients. Rozhledy v chirurgii: mesicnik Ceskoslovenske chirurgicke spolecnosti. 2012;91(4):209-15.
15. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. Journal of clinical oncology. 2002;20(6):1692-703.
16. Wang W, Songlin P, Sun Y, Zhang B, Jinhui W. miR-21 inhibitor sensitizes human OSCC cells to cisplatin. Molecular biology reports. 2012;39(5):5481-5.
17. Nayak S, Goel MM, Chandra S, Bhatia V, Mehrotra D, Kumar S, et al. VEGF-A immunohistochemical and mRNA expression in tissues and its serum levels in potentially malignant oral lesions and oral squamous cell carcinomas. Oral oncology. 2012;48(3):233-9.
| Files | ||
| Issue | Vol 6, No 1 (Winter 2019) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jcr.v6i1.1628 | |
| Keywords | ||
| Oral squamous cell carcinoma Early diagnosis VEGF mRNA miR-494 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Masoum Khani M, Mohamadnia A, Hosseini F, Bayat P, Bahrami N. Assessing VEGF mRNA and miR-494 expression in peripheral blood collected from patients suffering from oral squamous cell carcinoma. J Craniomaxillofac Res. 2019;6(1):34-38.
